pfizer glp-1 news scraps daily weight loss pill danuglipron after a liver injury Pfizer secures rights to new

In addition, one exploratory cohort that enroled 13 participants was used to evaluate digital tools and two open-label cohorts enroled 14 participants to evaluate dose-escalation strategies

Encouragingly, there may now be a better solution than any of these three hacks. Novo Nordisks Wegovy pill, an oral form of semaglutide, was FDA-approved in December 2025 and launched in January 2026

Not every patient needs this, but for patients with significant muscle mass concerns older adults, perimenopausal women, patients losing weight quickly at high doses it is worth considering

Perhaps the most crucial data point for long-term adherence is side effect management